- NEUTRAL
Quarterly Revenue Aura Biosciences Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Quarterly Net Profit Aura Biosciences Inc Jun-2026 Quarterly Net Profit is $-46 Million which is growth of -68.9% YoY.
6.220.13(2.13%)
589.8K
XNAS Volume
XNAS 05 Oct, 2026 5:30 PM (EDT)
Aura Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Aura Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | ||||||||||||||
Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 48.1 | 34.9 | 27.2 | 27.9 | 28.6 | 29 | 27.8 | 23.2 | 22.8 | 22.3 | 24.8 | 20.5 | 20.3 | ||
Operating Profit | -48.1 | -34.9 | -27.2 | -27.9 | -28.6 | -29 | -27.8 | -23.2 | -22.8 | -22.3 | -24.8 | -20.5 | -20.3 | |
| 2.3 | 1.2 | 1.5 | 1.8 | 1.7 | 1.6 | 2 | 2.3 | 2.5 | 2.7 | 2.6 | 2 | 2 | ||
Profit Before Tax | -45.6 | -33.7 | -25.5 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22 | -18.5 | -18.3 | |
Tax | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 | - | - | - | ||
| -45.6 | -33.7 | -25.6 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22.1 | -18.5 | -18.3 | ||
Diluted NI Avail to Com Stockholders Ann. | -45.6 | -33.7 | -25.6 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22.1 | -18.5 | -18.3 | |
Basic EPS | -0.5 | -0.5 | -0.4 | -0.4 | -0.5 | -0.6 | -0.5 | -0.4 | -0.4 | -0.4 | -0.5 | -0.5 | -0.5 | |
Diluted EPS After ExtraOrdinary | -0.5 | -0.5 | -0.4 | -0.4 | -0.5 | -0.6 | -0.5 | -0.4 | -0.4 | -0.4 | -0.5 | -0.5 | -0.5 | |
Number Of Shares End | 94.9 | 67.5 | 67.1 | 65.9 | 58 | 50.1 | 49.9 | 49.7 | 49.6 | 49.5 | 44.7 | 38.2 | 37.9 | |
Net Income Continuing Discontinued Operations | -45.6 | -33.7 | -25.6 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22.1 | -18.5 | -18.3 | |
Normalized Income | -45.6 | -33.7 | -25.6 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22.1 | -18.5 | -18.3 | |
Interest Income | 2.3 | 1.2 | 1.5 | 1.8 | 1.7 | 1.6 | 2 | 2.3 | 2.5 | 2.7 | 2.6 | 2 | 2 | |
Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Net Interest Income | 2.3 | 1.2 | 1.5 | 1.8 | 1.7 | 1.6 | 2 | 2.3 | 2.5 | 2.7 | 2.6 | 2 | 2 | |
EBIT | -48.1 | -34.9 | -27.2 | -27.9 | -28.6 | -29 | -27.8 | -23.2 | -22.8 | -22.3 | -24.8 | -20.5 | -20.3 | |
EBITDA | -47.8 | -34.6 | -27 | -27.6 | -28.3 | -28.7 | -27.5 | -22.9 | -22.5 | -22 | -24.5 | -20.1 | -20 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Reconciled Depr. | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
Profit From Continuing Operations | -45.6 | -33.7 | -25.6 | -26.1 | -27 | -27.5 | -25.8 | -21 | -20.3 | -19.7 | -22.1 | -18.5 | -18.3 | |
Normalized EBITDA | -47.8 | -34.6 | -27 | -27.6 | -28.3 | -28.7 | -27.5 | -22.9 | -22.5 | -22 | -24.5 | -20.1 | -20 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Aura Biosciences Inc competitor comparison and performance snapshot within industry
Aura Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Annual Revenue Aura Biosciences Inc Annual Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Annual Net Profit Aura Biosciences Inc Annual Net Profit is $-106 Million which is growth of -22.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | ||||||||||
Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | ||
Gross Profit Ann. | - | - | - | - | - | - | - | - | - | ||
Operating Exp. Ann. | 23.2% | 38.4% | 138.1 | 112.8 | 96.1 | 85 | 60.3 | 35.3 | 22.2 | 24.1 | |
Operating Profit Ann. | - | - | -138.1 | -112.8 | -96.1 | -85 | -60.3 | -35.3 | -22.2 | -24.1 | |
51.4% | - | 6.9 | 6.6 | 9.4 | 8.6 | 1.9 | 0 | -0 | |||
Other Exp. Ann. | - | - | 0.1 | -0.1 | 0.1 | -0.3 | -0 | -0.1 | |||
PBT Ann. | - | - | -130.9 | -106.1 | -86.8 | -76.3 | -58.8 | -35.3 | -22.2 | -24.2 | |
Tax Ann. | - | - | 0.1 | 0.1 | 0.1 | 0.1 | - | - | - | - | |
- | - | -131 | -106.2 | -86.9 | -76.4 | -58.8 | -46.2 | -22.2 | -24.2 | ||
Diluted NI Avail to Com Stockholders Ann. | - | - | -131 | -106.2 | -86.9 | -76.4 | -58.8 | -46.2 | -22.2 | -24.2 | |
EPS Ann. | - | - | -1.8 | -1.8 | -1.9 | -2 | -9 | -1.6 | -1.7 | ||
Diluted EPS Ann. | - | - | -1.8 | -1.8 | -1.9 | -2 | -9 | -1.6 | -1.7 | ||
Number Of Shares End | 28% | 27.9% | 67.1 | 49.9 | 44.7 | 32 | 29.2 | 19.6 | - | ||
Total Exp. Ann. | 23.2% | 38.4% | 112.8 | 96.1 | 85 | 60.3 | 35.3 | 22.2 | 24.1 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | -131 | -106.2 | -86.9 | -76.4 | -58.8 | -35.3 | -22.2 | -24.2 | |
Normalized Income Ann. | - | - | -131 | -106.2 | -86.9 | -76.6 | -58.4 | -35.2 | -22.2 | -24.1 | |
Interest Income Ann. | 51.4% | - | 6.9 | 6.6 | 9.4 | 8.6 | 1.9 | - | - | - | |
Interest Ann. | - | - | - | - | - | - | - | ||||
EBITDA Ann. | - | - | -137 | -111.7 | -94.9 | -83.7 | -59.1 | -34.4 | -21.4 | -23.7 | |
Reconciled Cost Of Rev. Ann. | - | - | - | - | - | - | - | - | - | ||
Reconciled Depr. Ann. | -2.9% | 6.6% | 1.1 | 1.1 | 1.2 | 1.3 | 1.2 | 0.8 | 0.8 | 0.5 | |
Profit From Continuing Operations Ann. | - | - | -131 | -106.2 | -86.9 | -76.4 | -58.8 | -35.3 | -22.2 | -24.2 | |
Normalized EBITDA Ann. | - | - | -137 | -111.7 | -94.9 | -83.9 | -58.8 | -34.4 | -21.4 | -23.6 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
17.4%
2Y CAGR
15.2%
3Y CAGR
23.2%
5Y CAGR
38.4%
Aura Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Total Shareholders Fund Aura Biosciences Inc Dec-2025 Total Shareholders Fund is $137 Million which is growth of -9.9% YoY.
- NEGATIVE
Total Assets Aura Biosciences Inc Dec-2025 Total Assets is $169 Million which is growth of -7.2% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
-8.9% | 50.3% | 169.4 | 182.5 | 255.1 | 223.9 | 160 | 22.1 | 37.1 | ||
4.6% | -24.3% | 32.5 | 30.5 | 29.2 | 28.4 | 7.7 | 130.8 | 124.5 | ||
-11.2% | - | 136.9 | 152 | 225.9 | 195.6 | 152.3 | -108.7 | -87.4 | ||
Total Capitalization Ann. | -11.2% | - | 136.9 | 152 | 225.9 | 195.6 | 152.3 | -108.7 | -87.4 | |
Tangible Assets Ann. | -11.2% | - | 136.9 | 152 | 225.9 | 195.6 | 152.3 | -108.7 | -87.4 | |
Working Capital Ann. | -11% | 52.8% | 131.4 | 145.7 | 219.4 | 186.2 | 146.4 | 15.8 | 27.2 | |
Invested Capital Ann. | -11.2% | - | 136.9 | 152 | 225.9 | 195.6 | 152.3 | -108.7 | -87.4 | |
Tangible Book Value Ann. | -11.2% | - | 136.9 | 152 | 225.9 | 195.6 | 152.3 | -108.7 | -87.4 | |
Borrowings Ann. | -5.9% | - | 17.4 | 18.8 | 19.6 | 20.9 | 1 | 0 | 0.1 | |
Net Debt Ann. | - | - | - | - | - | - | - | - | - | |
Share Issued Ann. | 18.9% | 16.8% | 63.6 | 50 | 49.4 | 37.8 | 29.2 | 29.2 | 28 | |
Number Of Shares End | 28% | 27.9% | 67.1 | 49.9 | 44.7 | 32 | 29.2 | 19.6 | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-7.2%
2Y CAGR
-18.5%
3Y CAGR
-8.9%
5Y CAGR
50.3%
Total Current Liabilities Ann.
1Y CHG
23.5%
2Y CAGR
21.8%
3Y CAGR
20.6%
5Y CAGR
46.8%
Total ShareHolders Funds Ann.
1Y CHG
-9.9%
2Y CAGR
-22.2%
3Y CAGR
-11.2%
Aura Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Book Value Per Share Aura Biosciences Inc Book Value Per Share is $3 which is growth of 8.1% YoY.
- NEUTRAL
ROE Aura Biosciences Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | -39.73% | -31.90% | -30.61% | -50.72% | -75.07% | -65.31% | |
ROE Ann. % | - | - | - | -46.01% | -36.26% | -33.78% | -211.88% | - | - | |
ROIC % | - | - | - | -15.1 | -11.9 | -9.4 | -193 | - | - | |
OPM Ann. % | - | - | - | - | - | - | - | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | - | - | - | - | - | - | |
Asset Turnover Ann. % | - | - | - | - | - | - | - | - | - | |
Working Capital Turnover Ann. | - | - | ||||||||
Quick Ratio Ann. | - | - | - | 10.1 | 18.3 | 18.1 | 20.5 | 6.5 | 5.3 | |
Current Ratio Ann. | - | - | - | 10.8 | 18.8 | 18.8 | 21.1 | 6.9 | 5.4 | |
Interest Coverage Ratio Ann. | - | - | - | - | - | - | - | -7,401 | -4,839 | |
LT Debt To Equity Ann. | - | - | - | 0.1 | 0.1 | 0.1 | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Aura Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Aura Biosciences Inc Cash From Operating Activity is $-85 Million which is growth of -6.2% YoY.
- POSITIVE
Net Cash Flow Aura Biosciences Inc Net Cash Flow is $28 Million which is growth of 398.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 |
|---|---|---|---|---|---|---|---|---|---|---|
- | - | -84.7 | -79.8 | -63.9 | -54.6 | -32.4 | -24.3 | -20.7 | ||
- | - | 35.6 | 68.8 | -114 | -67.9 | -2.1 | -0.8 | -2.2 | ||
-6.9% | 50.5% | 77.2 | 1.6 | 97.3 | 95.6 | 166.3 | 10 | 39.7 | ||
Cash Plus Cash Eqv. End Of Year Ann. | -21% | 28.1% | 60.3 | 32.5 | 41.9 | 122.4 | 149.2 | 17.5 | 32.5 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | - | - | 28 | -9.4 | -80.5 | -26.8 | 131.7 | -15.1 | 16.8 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -39.8% | 0% | 32.5 | 41.9 | 122.4 | 149.2 | 17.5 | 32.5 | 15.7 | |
Income Tax Paid Supplemental Data Ann. | - | - | - | - | - | - | - | - | - | |
Interest Paid Supplemental Data Ann. | - | - | - | - | - | - | - | - | - | |
Capex Ann. | - | - | -0.5 | -1.3 | -0.7 | -1.1 | -2.1 | -0.8 | -2.2 | |
Issuance Of Capital Stock Ann. | -17.9% | 39.7% | 52.6 | 95.8 | 95.2 | 165.9 | 9.9 | 39.7 | ||
Issuance Of Debt Ann. | - | - | - | - | - | - | - | - | - | |
Repayment Of Debt Ann. | - | - | - | - | - | - | - | -0 | -0 | |
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | -0 | ||
Free Cash Flow Ann. | - | - | -85.2 | -81.1 | -64.6 | -55.7 | -34.5 | -25.1 | -22.9 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
1Y CHG
-48.3%
Cash from Financing Act. Ann.
1Y CHG
4725%
2Y CAGR
-10.9%
3Y CAGR
-6.9%
5Y CAGR
50.5%
